Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan

Hanif, Farina; Mandhwani, Rajesh; Lail, Ghulamullah; Luck, Nasir Hassan; Aziz, Tahir

doi:10.6002/ect.mesot2018.p64

Cited by 3 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have observed 89.2% end-of-treatment response (ETR) and 100% SVR12 in our renal transplant population treated exclusively with SOF and RBV combination. Moreover, we also reported resolution of liver-related ascites in two out of four decompensated recipients[ 151 ].…”

Section: Renal Transplant Recipientsmentioning

confidence: 99%

“…Majority received SOF and RBV (78.5%) while remaining received SOF, DAC and RBV combination. ETR and SVR12 were achieved in 98.7% and 96.2%, respectively[ 151 ] Coral-1 study evaluated liver and RTRs. The study population including 12 non-cirrhotic RTRs received PrOD with and without RBV in genotype 1a and genotype 1b, respectively.…”

Section: Renal Transplant Recipientsmentioning

confidence: 99%

See 1 more Smart Citation

Revolution in the diagnosis and management of hepatitis C virus infection in current era

Hanif¹,

Majid²,

Luck³

et al. 2022

WJH

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is a major global public health problem, particularly in developing part of the world. Significant advances have been made in the early diagnosis and treatment of the disease. Its management has been particularly revolutionized during the past two decades. In this review, we summarize the major advances in the diagnostic and management armamentarium for chronic HCV infection. The focus of the present review is on the newer directly acting anti-viral agents, which have revolutionized the management of chronic HCV infection. Management of uncomplicated chronic HCV infection and of specific complications and special at-risk populations of patients will be covered in detail. Despite the advent and approval of highly effective and well tolerable oral agents, still many challenges remain, particularly the affordability, the equitable distribution and access to later drugs. The World Health Organization aims to eliminate viral hepatitis including HCV by 2030 since its poses a major public health threat. There is an urgent need to ensure uniform and early access to diagnostic and therapeutic facilities throughout the world if the later goal has to be realized.

show abstract

Section: Renal Transplant Recipientsmentioning

confidence: 99%

Section: Renal Transplant Recipientsmentioning

confidence: 99%

Revolution in the diagnosis and management of hepatitis C virus infection in current era

Hanif¹,

Majid²,

Luck³

et al. 2022

WJH

View full text Add to dashboard Cite

show abstract

“…Farina Muhammad Hanif et al from Karachi evaluated 62 Renal Transplant Recipients (RTRs) receiving SOF/RBV for 24 weeks, whereas 17 RTRs receiving combined SOF/DAC/RBV. End of treatment response was achieved in 78 recipients (98.1%) [134]. Same author in another study evaluated 37 RTRs receiving SOF/RBV achieving 100% SVR.…”

mentioning

confidence: 99%

“…Same author in another study evaluated 37 RTRs receiving SOF/RBV achieving 100% SVR. The genotype most commonly seen in RTR was genotype 1 (56.8%) [134]. Rajesh Mandhwani from Karachi evaluated 73 HCV positive patients with End stage renal disease (ESRD) on Hemodialysis who were treated with SOF/DAC/RBV for 3 months.…”

mentioning

confidence: 99%

An Update on National Consensus Practice Guidelines for the Treatment of Hepatitis C & Literature Review in Epidemiology of Hepatitis C in Pakistan - 2022

Syed,

Umar,

Khaar

et al. 2024

JRMC

View full text Add to dashboard Cite

Hepatitis C is a global health problem affecting around 58 million people worldwide and killing almost 0.29 million in on one year [1]. The world has united to fight against this lethal disease in 2016 with a moto to eliminate hepatitis by 2030. To achieve this goal WHO’s World Health Assembly has set some targets and individual countries have developed their own strategies to achieve those targets [2]. Pakistan has the 2nd highest prevalence of hepatitis C in the world with 5.8% viremia positive patients [3]. Pakistan is amongst the few countries that have been assisted by the Center for Disease Control and Prevention(CDC) to prevent and control Hepatitis[4]. With the availability of Direct Acting Antivirals(DAAs), the whole paradigm of treatment of hepatitis C has changed not only globally but also in Pakistan. However, the patients in Pakistan are unable to gain access to the latest DAAs at the pace, as they are available globally. International guidelines are being updated on regular basis as per global evidence, recommending such combinations which are not readily available to many parts of the world. Hence there is a dire need to develop national guidelines, keeping in consideration the efficacy of the drugs as well as their availability, in the broader canvas of achieving the targets of eliminating Hepatitis set by WHO. In this context, our consensus guidelines are an effort to fill the gap created because of upgraded scientific evidence and possible combinations available in our part of the world. Furthermore, quite some good research and evidence has also been shared in the literature from Pakistan during last five years (2016-2021). Hence a literature review has also been carried out to update our own epidemiologic data, risk factors and treatment responses to Hepatitis C in Pakistan.

show abstract

Adjuvant Use of Ribavirin With Treatment of Hepatitis C Virus in Kidney Transplant Recipients

Tiwari

Bashir²,

Verma³

et al. 2022

Indian Journal of Transplantation

View full text Add to dashboard Cite

Hepatitis C virus infection among kidney transplant recipients (KTRs) is an important public health concern worldwide. Evidence on available treatments given shows a greater variability for safety and efficacy, thus we performed this large analysis to present the pooled findings. PubMed/Medline, ScienceDirect, and Google Scholar were searched to identify observational studies of both interferon-based conventional treatment (CT) and recently approved direct-acting antivirals (DAAs), published before November 2020. Meta-analysis of effectiveness outcome (sustained virological response [SVR12]) and safety data (adverse events and discontinuation rate) was performed using a random-effect model. Subgroup analysis based on ± ribavirin with both treatments was performed to assess its relevance in clinical practice. Chi-square and I 2 tests were used to assess heterogeneity between the studies. Twenty-five and 9 observational records reporting on treatment with DAAs (n = 943) and CT (n = 125), respectively, are analyzed. The overall pooled estimate of SVR12 rate was found as 95.3%, (range: 92.6%–97%) with DAAs in comparison to 46.4% (range: 33.7%–59.6%) with CT. The pooled prevalence of adverse drug reactions (ADRs) in CT was higher as 47.8% than in DAAs as 23.8%, consequently showing a high discontinuation rate of 31.7% in CT as compared to 6.5% with DAAs. Subgroup analyses of both DAAs and interferon-based treatment ± ribavirin showed decreased effectiveness and increased ADR rates on adding ribavirin. The effectiveness of DDAs was found significantly higher than CT with a better safety profile in KTRs. Ribavirin did not provide any additional benefits while given in combination with either of the treatments available.

show abstract

Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan

Cited by 3 publications

References 27 publications

Revolution in the diagnosis and management of hepatitis C virus infection in current era

Revolution in the diagnosis and management of hepatitis C virus infection in current era

An Update on National Consensus Practice Guidelines for the Treatment of Hepatitis C & Literature Review in Epidemiology of Hepatitis C in Pakistan - 2022

Adjuvant Use of Ribavirin With Treatment of Hepatitis C Virus in Kidney Transplant Recipients

Contact Info

Product

Resources

About